Global immunotherapy drugs market is expected to reach USD 385.46 Billion by 2025, at a CAGR of 14.27% from 2018 to 2025. Increasing adoption of targeted therapy over traditional therapy, the emergence of biosimilars, increasing demand for monoclonal antibodies (MABs), fast track and orphan drug designations, and high prevalence rate of lifestyle diseases are the key factors that contribute the growth of the market.

Market Overview: Immunotherapy drugs are utilized to improve or smooth the insusceptible arrangement of the body. The immunotherapy drugs are also known as activation immunotherapies. They are generally utilized in the treatment of cancer. They act by empowering the resistant arrangement of the body and create an insusceptible reaction helping the generation of antibodies. Also governments are funding for the new development of the immunotherapy drugs. For instance, in 2017, the United States Food and Drug Association (FDA) has approved the investigation of a new immunotherapy drug for GBM tumours.  The antibiotics are created for killing the dangerous tumour cells. An expansion in the prevalence of cancer and various immune system diseases has led to an increase in the demand for immunotherapy drugs.

To Get Free Sample Report Visit @

Report Description:

  • The base year for the study has been considered 2017, historic year 2015 and 2016 and, the forecast period considered is from 2018 to 2025. The immunotherapy drugs market is analysed on the basis of and value (USD Million).
  • The study delivers a comprehensive analysis of global immunotherapy drugs market by type of drugs, therapy area, end user, and regions.
  • The report offers in-depth analysis of driving factors, opportunities, restraints, and challenges for gaining the key insight of the market. The report emphasizes on all the key trends that play a vital role in the enlargement of the market from 2018 to 2025.
  • Porter’s Five Forces model is used in order to recognize the competitive scenario in the global immunotherapy drugs market. This report incorporates the industry analysis which is focused on providing an extensive view of the immunotherapy drugs market.
  • The study also includes attractiveness analysis of type of drugs, therapy area, end user, and regions which are benchmarked based on their market size, growth rate and attractiveness in terms of present and future opportunity for understanding the future growth of the market.
  • The report provides company profile of the key players operating in the immunotherapy drugs market and a comparative analysis based on their business overviews, product offering, segment market share, regional presence, business strategies, innovations, mergers & acquisitions, recent developments, joint venture, collaborations, partnerships, SWOT analysis, and key financial information.
  • The market estimates have been evaluated by considering the effect of different political, economic, social, technological and legal factors which are based on our extensive secondary research, primary research, and in-house databases.

Global Immunotherapy Drugs Market Key Findings: All the segments have been analysed on global, regional and country basis. The study includes the analysis of more than 30 countries for each segment. Segmentation Analysis: The immunotherapy drugs market is segmented on the basis of type of drugs, therapy area, and end user.

  • Type of drugs segment includes monoclonal antibodies, adult vaccines, checkpoint inhibitors, interferons alpha & beta, interleukins, and other. The adult vaccines segment is further sub segmented into preventive vaccines and therapeutic vaccines. Checkpoint inhibitors segment is anticipated to grow with the highest CAGR of 16.54% over the forecast period. The first line of treatment in cancer leading to growing demand for immunotherapy drugs is the key factor to drive the demand of checkpoint inhibitors segment.
  • Therapy area segment is divided into cancer, autoimmune and inflammatory diseases, infectious diseases, other. The cancer segment is further divided into solid tumor and malignant. The cancer segment is dominating in the immunotherapy drugs market with the market size of USD 39.34 Billion in 2017. The major contributing factors for the growth of cancer segment are high preference for immunotherapy as a first line of treatment in cancer and increase in the use of cancer vaccines.
  • End user segment covers hospitals, clinics, other. The other segment is further sub-segmented into home healthcare centres and nursing home facilities. The hospitals segment is anticipated to grow with the highest CAGR of 17.36% over the forecast period.  The growing number of hospitals providing quick availability of immunotherapy drugs has increased the market share of hospitals segment.

Regional Segmentation Analysis:
The market is analysed on the basis of five regions namely North America, Europe, Asia Pacific, South America, and Middle East and Africa. North America region valued around USD 37.93 Billion in 2017 where as the Asia Pacific region is the fastest growing region and is expected to hold second dominant position in the global immunotherapy drugs market

  • Increase in the demand for convenience, low cost of manufacturing, and acceptable regulatory scenario were some of the factors that led to the growth of immunotherapy drugs market in North America region.
  • Asia Pacific is the fastest growing regional segment in the market due to low cost of manufacturing and acceptable regulatory.

Global Immunotherapy drugs market Competitive Analysis:
Key players in the immunotherapy drugs market are F. Hoffmann-La Roche, Merck, AbbVie, AstraZeneca, Johnson & Johnson, Bristol-Myers Squibb, Coherus BioSciences, ADC Therapeutics, ChemoCentryx, Boehringer Ingelheim, Argos Therapeutics, Agenus, CTI BioPharma, AVAX Technologies, Agensys, Biothera, Biogen, Alder Biopharmaceuticals, Aduro Biotech, Acorda Therapeutics, Eli Lilly, Amgen, Advaxis, and Bavarian Nordic. The F. Hoffmann-La Roche, Merck, Amgen Inc., and Johnson & Johnson are the leading players of the market. For instance, in 2017, National Institutes of Health (NIH) partnered with eleven biopharmaceutical companies for five years to develop advance cancer immunotherapy.

To Get Complete Information Visit @

Global Immunotherapy Drugs Market, By Type of Drugs:

  • Monoclonal Antibodies
  • Adult Vaccines
    • Preventive Vaccines
    • Therapeutic Vaccines
  • Checkpoint Inhibitors
  • Interferons Alpha & Beta
  • Interleukins
  • Other

Global Immunotherapy Drugs Market, By Therapy Area:

  • Cancer
    • Solid Tumor
    • Malignant
  • Autoimmune and Inflammatory Diseases
  • Infectious Diseases
  • Other

Global Immunotherapy Drugs Market, By End-User:

  • Hospitals
  • Clinics
  • Other
    • Home Healthcare Centers
    • Nursing Home Facilities

Global Immunotherapy Drugs Market, By Regions:

  • North America
    • U.S.
    • Canada
    • Mexico
  • Europe
    • Germany
    • France
    • Sweden
    • Netherlands
    • U.K.
    • Italy
    • Spain
    • Turkey
    • Switzerland
    • Belgium
    • Rest of Europe
  • Asia-Pacific
    • Japan
    • China
    • India
    • South Korea
    • Australia
    • Singapore
    • Malaysia
    • Thailand
    • Indonesia
    • Philippines
    • Rest of Asia-Pacific
  • South America
    • Brazil
    • Argentina
    • Colombia
    • Rest of South America
  • Middle East and Africa
  • Saudi Arabia
  • UAE
  • Egypt
  • Nigeria
  • South Africa
  • Rest of Middle East and Africa

Do Inquiry Before Buying:

*All our reports are customizable as per customer requirements. Please connect with our sales team (